Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-090404
Filing Date
2025-06-26
Accepted
2025-06-26 16:15:38
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 9814
2 EX-99.3 ck0000000000-ex99_3.htm EX-99.3 26579
  Complete submission text file 0000950170-25-090404.txt   38194
Mailing Address 888 SEVENTH AVENUE 37TH FLOOR NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE 37TH FLOOR NEW YORK NY 10106 212-468-5100
Wildcat Capital Management, LLC (Filed by) CIK: 0001582384 (see all company filings)

EIN.: 453715536 | State of Incorp.: DE | Fiscal Year End: 1213
Type: SCHEDULE 13D/A

Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Subject) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94600 | Film No.: 251080534
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)